Table 2.

Clinical materials of 134 male BC patients

Clinical parameters		Total (n=134)		Chemotherapy (n=78)		Non-chemotherapy (n=56)		p-Value
Age (years, mean±SD)		56.36±9.00		55.23±8.71		57.93±9.24		0.087
Tumour size (mm, mean±SD)		26.60±10.65		29.69±10.24		22.29±9.73		<0.001
Number of positive LNs (mean±SD)		1.51±2.88		2.54±3.41		0.07±0.38		<0.001
Histological grade (n, %)	I	64	47.76	44	56.41	20	35.71	0.018∗
	II	70	52.23	34	43.59	36	64.29
LVI (n, %)	Positive	54	40.30	40	51.38	14	25.00	0.002†
	Negative	80	59.70	38	84.72	42	75.00
Stage (n, %)	I	38	28.36	8	10.26	30	53.57	<0.001∗
	II	66	49.25	44	56.41	22	39.29
	III	30	22.39	26	33.33	4	7.14
HR (n, %)	Positive	114	85.07	60	76.92	54	96.43	0.002∗
	Negative	20	14.93	18	23.08	2	3.57
HER2 (n, %)	Positive	18	13.43	14	17.95	4	7.14	<0.001∗
	Negative	94	70.15	42	53.85	52	92.86
	Uncertain	22	16.42	22	28.20	0	0
Ki67 (n, %)	High	110	82.09	70	89.74	40	71.43	0.006†
	Low	24	17.91	8	10.26	16	28.57
Risk (n, %)	High	30	22.39	30	38.46	0	0	<0.001∗
	Medium	86	64.18	40	51.28	46	82.14
	Low	14	10.45	4	5.13	10	17.86

∗Wilcoxon rank-sum test.

†χ² test.

HER2, human epidermal growth factor 2; HR, hormone receptor; LN, lymph node; LVI, lymphovascualar invasion.